Novartis and Bristol Myers Squibb paused parts of their autoimmune CAR-T development programs after safety concerns, with reporting citing immune-related adverse events as the trigger. The actions extend beyond routine safety monitoring and reflect regulators’ and sponsors’ heightened scrutiny of immune dysregulation signals in early-stage immunotherapies. In Novartis’s case, additional reporting indicates three patient deaths in CD19-directed CAR-T trials following dangerous immune-system responses, prompting the halt and review. Bristol Myers reportedly initiated a voluntary pause of zola-cel in related autoimmune programs. These pauses can delay timelines for readouts and may force protocol revisions, inclusion/exclusion adjustments, and revised management strategies for cytokine release and off-tumor/off-biology immune effects. For the broader cell therapy market, the news is a reminder that CAR-T safety signals can escalate quickly from adverse events to operational suspension, shaping investor perception and partner diligence across next-generation constructs.